| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 104,40 | 105,30 | 11:54 | |
| 104,90 | 105,90 | 22.05. |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11:15 | Abivax: Nettoverlust sinkt - wichtige Phase-3-Daten zu Obefazimod stehen an | Die Abivax SA verzeichnete im ersten Quartal 2026 einen Nettoverlust von 48,5 Millionen Euro nach 52,4 Millionen Euro im Vorjahr. Der operative Verlust weitete sich auf 56,2 Millionen Euro nach 47,2... ► Artikel lesen | |
| Fr | Abivax reports Q1 results, ulcerative colitis trial data | ||
| Fr | EQS-News: ABIVAX: Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC | EQS-News: ABIVAX
/ Key word(s): Quarter Results/Study results
Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label... ► Artikel lesen | |
| Mi | Abivax S.A. - 6-K, Report of foreign issuer | ||
| 11.05. | EQS-News: ABIVAX: Abivax Announces Results of its May 11, 2026 Annual General Meeting | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11.05.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen |
